Pulmonary Nodules in an Infliximab-Treated Rheumatoid Arthritis Patient

A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Sarr MG, Kendrick ML, Nagorney DM (2001) Cystic neoplasms of the pancreas: benign to malignant epithelial neoplasms. Surg Clin North Am 81(3):497–509

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Luce JA (2000) Lymphoma, lymphoproliferative diseases and other primary malignant tumors. In: Murray J, Nadel J (eds) Textbook of respiratory medicine, 3rd edn. Saunders, Philadelphia, PA, pp 1453–1468

    Google Scholar 

  3. 3.

    Bullock WE (2000) Nocardiosis. In: Goldman L, Bennett JC (eds) Cecil textbook of medicine, 21st edn. Saunders, Philadelphia, PA, pp 1715–1717

    Google Scholar 

  4. 4.

    Dismukes WE (2000) Histoplasmosis, coccidiomycosis, blastomycosis. In: Goldman L, Bennett JC (eds) Cecil textbook of medicine, 21st edn. Saunders, Philadelphia, PA, pp 1860–1866

    Google Scholar 

  5. 5.

    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72(9):3666–3670

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A (1985) Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 161(5):984–995

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330(6149):662–664

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2(5):364–371

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Nathan CF (1987) Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. Clin Invest 80(6):1550–1560

    CAS  Article  Google Scholar 

  11. 11.

    Criscione LG, St Clair EW (2002) Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 14(3):204–211

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Nathan CF, Ehrt S (2003) Nitric oxide and tuberculosis. In: Rom W, Garay S (eds) Tuberculosis, 1st edn. Lippincott, New York

    Google Scholar 

  13. 13.

    Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56(5):731–740

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Bean AG, Roach DR, Briscoe H, France MP, Korner H (1999) Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 162(6):3504–3511

    PubMed  CAS  Google Scholar 

  15. 15.

    Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168(9):4620–4627

    PubMed  CAS  Google Scholar 

  16. 16.

    Trevejo JM, Marino MW, Philpott N, Josien R, Richards EC, Elkon KB, Falck-Pedersen E (2001) TNF-alpha-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci U S A 98(21):12162–12167

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Shiloh MU, MacMicking JD, Nicholson S, Brause JE, Potter S (1999) Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10(1):29–38

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Maianski NA, Roos D, Kuijpers TW (2002) Tumor necrosis factor {alpha} induces a caspase-independent death pathway in human neutrophils. Blood 101(5):1987–1995

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Hodge-Dufour J, Marino MW, Horton MR, Jungbluth A, Burdick MD (1998) Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc Natl Acad Sci U S A 95(23):13806–13811

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2(6):561–572

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Paget SA (2001) Postmarketing adverse event data for TNF-alpha antagonists. <http://www.hss.edu/Professionals/Conditions/Rheumatoid-Arthritis/Postmarketing-Adverse-Event-TNF-Alpha> (Accessed on December 7, 2006)

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Anne R. Bass MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bass, A.R., Schneider, R., Sanders, A. et al. Pulmonary Nodules in an Infliximab-Treated Rheumatoid Arthritis Patient. HSS Jrnl 3, 119–125 (2007). https://doi.org/10.1007/s11420-006-9032-1

Download citation

Keywords

  • Infliximab
  • Pulmonary Nodule
  • Histoplasmosis
  • Purify Protein Derivative
  • Coccidioidomycosis